Articles related to MENTAL HEALTH

With treatment penetration rates less than 20% for those with serious addictions, this viewpoint offers up a strategic clinical approach that mimics the diabetes field, using the term preaddiction, a commonly understood, motivating term (such as prediabetes) that could engender broader clinical efforts to effect the planned strategy.

The research shows that chronic pain, inflammatory bowel disease, cancer, and migraines all play a role in the development of mental diseases. Healthcare practitioners should take a careful history and keep in mind comorbidities when treating patients for any of these conditions.

In this Q&A, Dr. Vincent Millischer describes the surprising association between lithium clearance and serum lithium as well as the role that genetics may play in helping to determine the proper lithium dosage for each patient.

In this 30-minute, 0.50 credit CME activity, participants will be better able to define treatment response, remission and treatment resistance in MDD; identify patients with inadequate response to antidepressants who may benefit from treatment modification; select an appropriate next-step treatment strategy for a patient with partial response to an antidepressant; and compare pharmacologic and adverse effect profiles of SGAs approved for adjunctive treatment of MDD.

With fast symptom relief and reinforcing effects, benzodiazepines were once the gold standard for treating insomnia and anxiety. As opioids dominate headlines along with the public health crisis of drug overdose deaths, is it time to reconsider benzodiazepines as a course of treatment?

To date, no Cdk5 inhibitor has been approved to treat any neuropsychiatric or degenerative diseases due to challenges at the blood-brain barrier. James Bibb, Ph.D., and colleagues seek to change that notion with their brain-permeable compound, 25-106.